Castle Biosciences Inc (CSTL) financials
Castle Biosciences revenue and earnings by year
Castle Biosciences's revenue was $344 million in the fiscal year to December 31, 2025, up 3.7% from the year before. Net income was -$24.2 million, -7.0% of revenue. Since the fiscal year to December 31, 2017, revenue has grown 49.6% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 344 | 332 | 220 | 137 | 94 | 63 | 52 | 23 | 14 |
| Revenue growth | 3.7% | 51.1% | 60.4% | 45.7% | 50.2% | 20.8% | 127.6% | 65.7% | — |
| Gross profit | 273 | 272 | 175 | 105 | 78 | 53 | 45 | 17 | 9 |
| Gross margin | 79.4% | 81.9% | 79.5% | 76.6% | 83.2% | 84.5% | 85.9% | 76.8% | 64.2% |
| Operating income | -43 | 9 | -68 | -91 | -40 | -7 | 7 | -4 | -11 |
| Operating margin | -12.4% | 2.6% | -30.9% | -66.5% | -42.6% | -10.4% | 14.1% | -16.8% | -79.2% |
| Net income | -24 | 18 | -57 | -67 | -31 | -10 | 5 | -6 | -12 |
| Net margin | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% | -16.4% | 10.2% | -27.9% | -89.9% |
| Diluted EPS | -$0.83 | $0.62 | -$2.14 | -$2.58 | -$1.24 | -$0.51 | — | — | — |
| Free cash flow | 28 | 37 | -19 | -47 | -22 | 5 | 6 | -13 | -13 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CSTL in Markets.
How Castle Biosciences makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Non Dermatologic | $54.8M | 53.0% |
| Dermatologic | $48.7M | 47.0% |
See also: CSTL returns
No forecast, no recommendation. This page describes Castle Biosciences Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.